These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
738 related articles for article (PubMed ID: 27121688)
1. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Steegmann JL; Baccarani M; Breccia M; Casado LF; García-Gutiérrez V; Hochhaus A; Kim DW; Kim TD; Khoury HJ; Le Coutre P; Mayer J; Milojkovic D; Porkka K; Rea D; Rosti G; Saussele S; Hehlmann R; Clark RE Leukemia; 2016 Aug; 30(8):1648-71. PubMed ID: 27121688 [TBL] [Abstract][Full Text] [Related]
2. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners. Wong SF; Mirshahidi H Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900 [TBL] [Abstract][Full Text] [Related]
3. Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Tinsley SM J Clin Nurs; 2010 May; 19(9-10):1207-18. PubMed ID: 20345830 [TBL] [Abstract][Full Text] [Related]
4. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Irvine E; Williams C Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655 [TBL] [Abstract][Full Text] [Related]
5. Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid Leukemia. Bettiol A; Marconi E; Lombardi N; Crescioli G; Gherlinzoni F; Walley T; Vannacci A; Chinellato A; Giusti P Clin Drug Investig; 2018 Sep; 38(9):837-844. PubMed ID: 30043130 [TBL] [Abstract][Full Text] [Related]
6. [Prevalence of Adverse Effects of Tyrosine Kinase Inhibitors Used in Management of Chronic Myeloid Leukemia at Sidi Bel-Abbès University Hospital Center]. Matmour D; Si-Ali N; Benmehimda NC; Beloufa S; Belfrak F; Mahi E; Merad Y; Toumi H; Benlazar M Ann Pharm Fr; 2022 Nov; 80(6):932-942. PubMed ID: 35469781 [TBL] [Abstract][Full Text] [Related]
7. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Jain P; Kantarjian H; Boddu PC; Nogueras-González GM; Verstovsek S; Garcia-Manero G; Borthakur G; Sasaki K; Kadia TM; Sam P; Ahaneku H; O'Brien S; Estrov Z; Ravandi F; Jabbour E; Cortes JE Blood Adv; 2019 Mar; 3(6):851-861. PubMed ID: 30885996 [TBL] [Abstract][Full Text] [Related]
8. Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Rea D Ann Hematol; 2015 Apr; 94 Suppl 2():S149-58. PubMed ID: 25814081 [TBL] [Abstract][Full Text] [Related]
9. Current perspectives for the treatment of chronic myeloid leukemia. Aladağ E; Haznedaroğlu İC Turk J Med Sci; 2019 Feb; 49(1):1-10. PubMed ID: 30761815 [TBL] [Abstract][Full Text] [Related]
11. The safety of Bosutinib for the treatment of chronic myeloid leukemia. Kong JH; Khoury HJ; Kim AS; Hill BG; Kota V Expert Opin Drug Saf; 2017 Oct; 16(10):1203-1209. PubMed ID: 28774214 [TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system. Malkan UY; Haznedaroglu IC Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5493-5506. PubMed ID: 37401285 [TBL] [Abstract][Full Text] [Related]
14. Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014. Kawano N; Yoshida S; Kawano S; Kuriyama T; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I J Clin Exp Hematop; 2016; 56(1):34-42. PubMed ID: 27334856 [TBL] [Abstract][Full Text] [Related]
15. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years. Lang AS; Mounier M; Roques M; Chretien ML; Boulin M J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674 [TBL] [Abstract][Full Text] [Related]
16. The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations. Soysal T; Eskazan AE; Serin I; Sadri S; Keskin D; Ozgur Yurttas N; Berk S; Erdogan Ozunal I; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Ozbek U; Aydin Y Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e377-e384. PubMed ID: 31088736 [TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis. Fachi MM; Tonin FS; Leonart LP; Aguiar KS; Lenzi L; Figueiredo BC; Fernandez-Llimos F; Pontarolo R Eur J Cancer; 2018 Nov; 104():9-20. PubMed ID: 30296736 [TBL] [Abstract][Full Text] [Related]
19. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia. Yilmaz M; Jabbour E Semin Oncol; 2015 Dec; 42(6):876-86. PubMed ID: 26615132 [TBL] [Abstract][Full Text] [Related]
20. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Steegmann JL; Cervantes F; le Coutre P; Porkka K; Saglio G Leuk Lymphoma; 2012 Dec; 53(12):2351-61. PubMed ID: 22616642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]